title: Buprenorphine for cancer pain: is it ready for prime time?
abstract: Buprenorphine (BUP) is a semisynthetic derivative of the opium alkaloid thebaine found in the poppy Papaver somniferum. Its chemical structure contains the morphine structure but differs by having a cyclopropylmethyl group. Buprenorphine is a potent µ opioid agonist. Buprenorphine undergoes extensive first-pass metabolism in the liver and gut. The development of a transdermal BUP formulation in 2001 led to its evaluation in cancer pain. This article provides the practitioner with an update on the current role of BUP in cancer care. It highlights data suggesting effectiveness in various types of cancer pain. The article reviews pharmacology, routes of administration, adverse effects, drug interactions, and cost considerations.
authors.affiliation: Mayo Clinic Arizona, Phoenix, AZ, USA prommer.eric@mayo.edu.
authors.forename: Eric
authors.initials: E
authors.lastname: Prommer
mesh_terms: D000701:Analgesics, Opioid / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002047:Buprenorphine / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000072716:Cancer Pain / Q000188:drug therapy*; D006801:Humans; D010166:Palliative Care / Q000379:methods*
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine
keywords: buprenorphine; cancer; neuropathic; opioid; pain; renal insufficiency